| Preface |
|
vii | |
| Acknowledgements |
|
ix | |
| CHAPTER 1 Introduction |
|
|
|
|
1 | (4) |
|
|
|
5 | (2) |
| CHAPTER 2 Historical Antecedents |
|
|
|
|
7 | (1) |
|
|
|
8 | (1) |
|
III. Social Organization, Health, and Healing |
|
|
9 | (1) |
|
IV. Early Ideas about Health and Disease |
|
|
10 | (4) |
|
|
|
10 | (1) |
|
|
|
11 | (3) |
|
V. Empirical Approaches to Health |
|
|
14 | (1) |
|
|
|
15 | (4) |
|
A. Microbes and Innate Defenses |
|
|
15 | (1) |
|
B. Regulation of Life-sustaining Activities |
|
|
16 | (2) |
|
|
|
18 | (1) |
|
|
|
19 | (1) |
|
|
|
20 | (3) |
| CHAPTER 3 Immune System Basics |
|
|
|
|
23 | (1) |
|
II. Molecular Self/Nonself Discrimination |
|
|
24 | (1) |
|
III. Cell Types, Proteins, and Genes |
|
|
24 | (1) |
|
IV. Immune System Cell Types and Complement |
|
|
25 | (3) |
|
V. Immune Cell Functions and Inflammation |
|
|
28 | (3) |
|
VI. Human Leukocyte Antigen System |
|
|
31 | (1) |
|
VII. Antigen Presentation |
|
|
32 | (2) |
|
VIII. Natural Killer Cells |
|
|
34 | (1) |
|
IX. B Lymphocytes, Antibody Structure, and Diversity |
|
|
35 | (2) |
|
|
|
37 | (5) |
|
A. T-Cell Receptor Diversity and CD Markers |
|
|
37 | (1) |
|
B. Helper T Lymphocytes (CD4+) |
|
|
38 | (2) |
|
C. T-Cell Help of Antibody Production |
|
|
40 | (1) |
|
D. T-Cell Help of Cytotoxicity |
|
|
41 | (1) |
|
XI. Cytokines, Chemokines, and Cell Adhesion Molecules |
|
|
42 | (4) |
|
XII. Lymphoid Organs and Leukocyte Traffic |
|
|
46 | (3) |
|
XIII. Inmiune Activation/Deactivation and Memory |
|
|
49 | (1) |
|
XIV. Development of Immune Functions |
|
|
50 | (1) |
|
XV. Measures of Immune Function |
|
|
51 | (2) |
|
|
|
53 | (2) |
|
|
|
55 | (3) |
| CHAPTER 4 Endocrine-Immune Modulation |
|
|
|
|
58 | (1) |
|
|
|
59 | (4) |
|
|
|
59 | (1) |
|
|
|
60 | (2) |
|
|
|
62 | (1) |
|
III. Cytokines, Hormones, and Their Receptors |
|
|
63 | (1) |
|
IV. Anterior Pituitary Hormones and Immune Function |
|
|
64 | (9) |
|
|
|
64 | (2) |
|
|
|
66 | (1) |
|
C. The Pituitary-Adrenal Asis: POMC Peptides (ACTH, β-Endorphin) and Glucocorticolds |
|
|
67 | (4) |
|
D. The Pituitary-Gonadal Axis: Gonadotropins and Gonadal Steroids |
|
|
71 | (1) |
|
E. The Pituitary Thyroid Axis: Thvrotropiu and Thyroid Hormones |
|
|
72 | (1) |
|
V. Posterior Pituitary Gland Hormones and Immune Function |
|
|
73 | (1) |
|
|
|
73 | (1) |
|
|
|
73 | (1) |
|
VI. Other Hormones and Immune Function |
|
|
74 | (2) |
|
|
|
74 | (1) |
|
|
|
74 | (1) |
|
|
|
75 | (1) |
|
|
|
76 | (1) |
|
A. Pituitary Regulation of Thymus |
|
|
76 | (1) |
|
B. Thymus Regulation of Pituitary |
|
|
76 | (1) |
|
C. Hormones and Thymocyte Development |
|
|
77 | (1) |
|
VIII. Concluding Comments |
|
|
77 | (2) |
|
|
|
79 | (3) |
| CHAPTER 5 Neuroimmune Modulation |
|
|
|
|
82 | (1) |
|
II. Peripheral Nervous System |
|
|
82 | (4) |
|
A. Somatoscnsory Pathways |
|
|
83 | (1) |
|
B. Visceral Sensory Pathways |
|
|
84 | (1) |
|
C. Autonomic Nervous System |
|
|
84 | (1) |
|
D. Enteric Nervous System |
|
|
85 | (1) |
|
III. Peripheral Nervous System Innervation of Lymphoid Organs |
|
|
86 | (1) |
|
A. Bone Marrow and Thymus |
|
|
86 | (1) |
|
B. Spleen, Lymph Nodes, and Mucosa-Associated Lymphoid Tissue |
|
|
86 | (1) |
|
IV. Chemical Signaling in the Periphery |
|
|
87 | (2) |
|
A. Classical Neurotransmitters |
|
|
87 | (1) |
|
|
|
88 | (1) |
|
|
|
88 | (1) |
|
|
|
89 | (1) |
|
V. Functional Effects of Peripheral Neuroimmune Interactions |
|
|
89 | (3) |
|
VI. Central Nervous System |
|
|
92 | (2) |
|
VII. Bidirectional Central Nervous System-Immune System Interactions |
|
|
94 | (4) |
|
|
|
94 | (1) |
|
B. Subcortical Responses to Immunization |
|
|
95 | (1) |
|
|
|
96 | (2) |
|
VIII. Learning and Immune Responses |
|
|
98 | (1) |
|
IX. Personality and Immune Function |
|
|
99 | (2) |
|
|
|
101 | (1) |
|
|
|
102 | (1) |
| CHAPTER 6 Stress, Contextual Change, and Disease |
|
|
|
|
103 | (1) |
|
II. Selye's Concept of Stress |
|
|
103 | (3) |
|
III. Ranking Life Events as Stressful |
|
|
106 | (2) |
|
IV. Stress as Contextual Change |
|
|
108 | (1) |
|
|
|
109 | (1) |
|
|
|
109 | (1) |
|
VII. Nonliving Environment |
|
|
110 | (1) |
|
VIII. Individual as Context |
|
|
111 | (2) |
|
IX. Disease as Contextual Change |
|
|
113 | (1) |
|
|
|
114 | (1) |
|
|
|
115 | (2) |
| CHAPTER 7 Psychosocial Stress: Neuroendocrine and Immune Effects |
|
|
|
|
117 | (1) |
|
|
|
118 | (1) |
|
|
|
118 | (1) |
|
B. Individual Attributes/Personality |
|
|
119 | (1) |
|
|
|
119 | (1) |
|
III. Effects on Endocrine Activity |
|
|
119 | (3) |
|
A. Pituitary-Adrenal Axis |
|
|
120 | (1) |
|
B. Pituitary-Gonadal Axis |
|
|
121 | (1) |
|
C. Other Axes and Hormones |
|
|
121 | (1) |
|
IV. Effects on Autonomic and Peripheral Neural Activity |
|
|
122 | (1) |
|
A. Classical Neurotransmitters |
|
|
122 | (1) |
|
|
|
122 | (1) |
|
V. Effects on the Central Nervous System |
|
|
123 | (1) |
|
VI. Effects on the Immune System |
|
|
123 | (6) |
|
|
|
124 | (1) |
|
|
|
125 | (1) |
|
C. Cell-Mediated Immunity |
|
|
126 | (2) |
|
D. Cautions and Integration |
|
|
128 | (1) |
|
VII. Neuroendocrine-Immune Pathways |
|
|
129 | (1) |
|
VIII. Concluding Comments |
|
|
129 | (2) |
|
|
|
131 | (3) |
| CHAPTER 8 Infection, Allergy, and Psychosocial Stress |
|
|
|
|
134 | (1) |
|
|
|
134 | (9) |
|
|
|
135 | (2) |
|
|
|
137 | (1) |
|
C. Infection and Other Diseases |
|
|
138 | (1) |
|
D. Psychosocial Stress, Immunity, and Infection |
|
|
139 | (4) |
|
|
|
143 | (6) |
|
|
|
143 | (1) |
|
B. Prevalence and Genetics |
|
|
144 | (1) |
|
C. Environmental Cofactors |
|
|
145 | (1) |
|
|
|
145 | (2) |
|
E. Complexity of Allergic Responses |
|
|
147 | (1) |
|
F. Psychosocial Stress, Immunity, and Allergy |
|
|
148 | (1) |
|
|
|
149 | (2) |
|
|
|
151 | (3) |
| CHAPTER 9 Cancer, Autoimmunity, and Psychosocial Stress |
|
|
|
|
154 | (1) |
|
|
|
154 | (10) |
|
A. Cancer as an Expanding Clone |
|
|
155 | (2) |
|
B. Environmental Carcinogenesis |
|
|
157 | (1) |
|
C. Defenses against Cancer |
|
|
158 | (1) |
|
D. Psychosocial Stress, Immunity, and Cancer |
|
|
159 | (4) |
|
E. Could Psychosocial Factors be Irrelevant? |
|
|
163 | (1) |
|
|
|
164 | (11) |
|
A. Clonal Selection Theory and Normal Autoimmunity |
|
|
164 | (1) |
|
B. Prevalence of Autoimmune Disorders |
|
|
165 | (1) |
|
|
|
165 | (2) |
|
D. Infection Triggers Autoimmunity |
|
|
167 | (1) |
|
E. Cancer Triggers Autoimmunity |
|
|
168 | (1) |
|
F. Toxic Chemicals Trigger Autoimmunity |
|
|
168 | (1) |
|
G. Susceptibility to Autoimmunity |
|
|
169 | (1) |
|
H. Psychosocial Stress and Autoimmune Disorder |
|
|
170 | (4) |
|
I. Gender and Autoimmunity |
|
|
174 | (1) |
|
|
|
175 | (2) |
|
|
|
177 | (3) |
| CHAPTER 10 Immune Activity and Psychopathology |
|
|
|
|
180 | (1) |
|
II. Access to Brain by Pathogens |
|
|
181 | (1) |
|
III. Immune Activity within the Brain |
|
|
181 | (3) |
|
|
|
182 | (1) |
|
B. Cytokine Effects in Brain |
|
|
182 | (1) |
|
C. Optimal Immune Response in Brain |
|
|
183 | (1) |
|
D. Consequences of Immune Activity in the Brain |
|
|
183 | (1) |
|
IV. Nervous System Infections and Behavior |
|
|
184 | (6) |
|
A. Neurological Disorders |
|
|
185 | (1) |
|
B. Neurodegenerative Disorders |
|
|
186 | (1) |
|
|
|
187 | (1) |
|
|
|
187 | (2) |
|
|
|
189 | (1) |
|
F. Human Immunodeficiency Virus |
|
|
189 | (1) |
|
V. Autoimmunity, Malignancy, and Behavior |
|
|
190 | (1) |
|
A. Systemic Lupus Erythematosus |
|
|
190 | (1) |
|
B. Parancoplastic Disorders |
|
|
191 | (1) |
|
VI. Sensing Peripheral Immune Activity |
|
|
191 | (2) |
|
A. Cytokines Alter Mental Processes and Behavior |
|
|
191 | (1) |
|
B. Channels of Communication |
|
|
192 | (1) |
|
C. Functional Significance |
|
|
193 | (1) |
|
|
|
193 | (1) |
|
VIII. Behavioral Disorders that Resemble Sickness Behavior |
|
|
194 | (2) |
|
A. Chronic Fatigue and Pain |
|
|
194 | (1) |
|
|
|
195 | (1) |
|
IX. Psychiatric Disorders with a Link to Infection |
|
|
196 | (7) |
|
A. Autism and Pervasive Developmental Disorders |
|
|
196 | (1) |
|
B. Attention-Deficit/Hyperactivity Disorder |
|
|
197 | (1) |
|
C. Childhood Obsessive-Compulsive Disorder and Tourette's Syndrome |
|
|
198 | (1) |
|
D. Schizophrenia and Other Psychoses |
|
|
199 | (4) |
|
|
|
203 | (1) |
|
|
|
204 | (3) |
| CHAPTER 11 Immune Function Enhancement |
|
|
|
|
207 | (1) |
|
II. Beliefs, Suggestion, and Expectations |
|
|
208 | (5) |
|
|
|
209 | (1) |
|
|
|
210 | (1) |
|
|
|
211 | (1) |
|
D. Expectations are Patterns of Neural Activity |
|
|
211 | (1) |
|
E. Expectation and Immune Activity |
|
|
212 | (1) |
|
|
|
213 | (1) |
|
IV. Expression of Emotion |
|
|
213 | (1) |
|
|
|
214 | (1) |
|
VI. Exercise and Physical Activity |
|
|
215 | (2) |
|
|
|
215 | (1) |
|
B. Acute-Phase Proteins, Antibodies, and Cytokines |
|
|
216 | (1) |
|
|
|
217 | (4) |
|
|
|
218 | (1) |
|
B. Individual Factors and Nonlinear Effects |
|
|
218 | (1) |
|
C. Antioxidants: Vitamins and Minerals |
|
|
219 | (1) |
|
|
|
220 | (1) |
|
E. Modulation by Hormones |
|
|
220 | (1) |
|
VIII. Concluding Continents |
|
|
221 | (1) |
|
|
|
222 | (3) |
| CHAPTER 12 Integration and Implications |
|
|
|
|
225 | (1) |
|
|
|
225 | (3) |
|
III. Microenvironments and Complexity |
|
|
228 | (1) |
|
IV. Unnecessary and Insufficient |
|
|
228 | (1) |
|
V. Implications for Research |
|
|
229 | (3) |
|
A. Limits of Reductionism |
|
|
229 | (1) |
|
B. Major Dimensions of Health State Space |
|
|
229 | (3) |
|
VI. Implications for Health Care |
|
|
232 | (1) |
|
A. Holistic-Expanded Perspective |
|
|
232 | (1) |
|
B. Individualized Health Education |
|
|
232 | (1) |
|
VII. Economic Considerations |
|
|
233 | (1) |
|
VIII. Concluding Comments |
|
|
233 | (1) |
|
|
|
234 | (1) |
| Glossary |
|
235 | (26) |
| Index |
|
261 | |